Stock 61Y MARINUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Marinus Pharmaceuticals, Inc. Deutsche Boerse AG

Equities

61Y

US56854Q2003

Real-time Estimate Tradegate
Other stock markets
 09:00:01 17/06/2024 BST 		5-day change 1st Jan Change
1.375 EUR +4.96% Intraday chart for Marinus Pharmaceuticals, Inc. -2.94% -86.46%
06-06 Marinus Pharmaceuticals, Inc. Enter into an Amendment to Its Previously Disclosed Credit Agreement with Oaktree Fund Administration, Llc CI
05-17 Sector Update: Health Care Stocks Mixed Late Afternoon MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - MRNS
NE
Pomerantz Law Firm Announces the Filing of a Class Action Against Marinus Pharmaceuticals, Inc. - MRNS
PR
Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc. (MRNS) Investors
BU
Marinus Pharmaceuticals, Inc. Stockholders with Large Losses Should Contact Robbins LLP About Their Rights in Connection with the MRNS Class Action Lawsuit
BU
MRNS Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
PR
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit
PR
MRNS Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
BU
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc. (MRNS) Investors
BU
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Marinus Pharmaceuticals, Inc. (MRNS) on Behalf of Investors
BU
Law Offices of Howard G. Smith Announces Investigation of Marinus Pharmaceuticals, Inc. (MRNS) on Behalf of Investors
BU
The Law Offices of Frank R. Cruz Announces Investigation of Marinus Pharmaceuticals, Inc. (MRNS) on Behalf of Investors
BU
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schal Law Firm
PR
Marinus Pharmaceuticals Investor Notice: Robbins LLP Reminds Stockholders to Seek Representation in the MRNS Class Action
BU
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Marinus Pharmaceuticals, Inc. with Losses to Contact the Firm
BU
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - MRNS
PR
MRNS Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
PR
MRNS Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
BU
Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Marinus Pharmaceuticals, Inc. Investors – MRNS
BU
Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program
AQ
Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRNS Stock
  4. 61Y Stock
  5. News Marinus Pharmaceuticals, Inc.
  6. Press Releases
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW